Lesotho
Tuberculosis profile
| High HIV burden |
Population  2013 2.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.96 (0.38–1.8) 46 (18–86)
Mortality (HIV+TB only) 5.2 (2.9–8.1) 250 (142–390)
Prevalence  (includes HIV+TB) 13 (6.8–20) 613 (327–987)
Incidence  (includes HIV+TB) 19 (14–26) 916 (659–1 267)
Incidence (HIV+TB only) 15 (10–20) 703 (498–971)
Case detection, all forms (%) 50 (36–70)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.9 (0.2–2.6) 5.7 (1.2–16)
MDR-TB cases among notified pulmonary
TB cases
68 (15–200) 92 (19–250)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 649   436
Pulmonary, clinically diagnosed 4 902   0
Extrapulmonary 1 568   0
       
Total new and relapse 9 555    
Previously treated, excluding relapses 1 183    
Total cases notified 10 738    
Among 8 916 new cases:
473 (5%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 66 (2%) 79 (5%) 1 470
Laboratory-confirmed RR-/MDR-TB cases     145
Patients started on MDR-TB treatment     163
TB/HIV 2013 Number (%)
TB patients with known HIV status 9 756 (91)
HIV-positive TB patients 7 234 (74)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 111 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 5 071 (70)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 71
Previously treated cases, excluding relapse, registered in 2012 63
HIV-positive TB cases, all types, registered in 2012 69
RR-/MDR-TB cases started on second-line treatment in 2011 61
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 2.4
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 8
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 3.1
% Funded domestically <1%
% Funded internationally 99%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-28 Data: www.who.int/tb/data